References
- Alter HJ, Seelf LB. Recovery, persistence, and sequealea in hepatitis C virus infection: a perspective on long-term outcomes. Semin. Liver Dis. 20,17–35 (2000).
- •Key issue in the natural hepatitis C virus (HCV) infection.
- Armstrong GL, Alter MJ. McQuillan GM et aL The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology31, 777–782 (2000).
- Wong JB, McQuillan GM, McHutchison JG et aL Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am. J. Pub. Health, 90, 1562–1569 (2000).
- Seeff LB. Natural history of hepatitis C. Arn. J. Med. 107, S10—S15 (1999).
- Freeman AJ, Dore GJ, Law MG et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology34,809–816 (2001).
- ••Systematic review of studies of the naturalhistory of hepatitis C (HCV) infection.
- Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatits C? GastroenteroL HepatoL 17,423–430 (2002).
- •Model of natural history of HCV infection.
- McHutchison JG, Gordon SC, Schiff ER et al. Interferon-a-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl. J. Med. 229,1485-1492 (1998).
- National Institute for Clinical Excellence. Interferon-a (pegylated and non pegylated) and ribavirin for the treatment of chronic hepatitis C. Technology Appraisal Guidance: 1–38, No 75 (2004).
- Bonis PA, Ioannidis JP, Cappelleri JC et al. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics. Hepatology26, 1045–1044 (1997).
- Manns MP, McHutchison JG, Gordon SC et al. Peginterferon-a-2b plus ribavirin compared with interferon-a-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358, 958–965 (2001).
- •Pivotal study which have examined the efficacy of pegylated (peg) interferon-a2b plus ribavirin in the treatment of chronic hepatitis C (CHC).
- Fried MW, Schiffman ML, Reddy KJ et aL Peginterferon-a-2a plus ribavirin for chronic hepatitis C virus infection. N Engl. J. Med. 347,975-982 (2002).
- •Pivotal study which have examined the efficacy of peginterferon-a2b plus ribavirin in the treatment of CHC.
- Nixon J, Khan KS, Kleijnen J. Summarizing economic evaluations in systematic reviews: a new approach. Br. Med. j322, 1596–1598 (2001).
- Kuehne FC, Bethe U, Freeberg K, Goldie SJ. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch. Intern. Med. 162 (22), 2545–2556 (2002).
- •Cost-effectiveness analysis of alternative management strategies for CHC in HIV-coinfected patients with moderate hepatitis.
- Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 290(2), 228–237 (2003).
- •Cost-effectiveness analysis of newer treatment for CHC in population of asymptomatic, HCV seropositive but otherwise healthy individuals.
- Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK, International Hepatitis Interventional Therapy Group. Economic and clinical effects of evaluating rapid viral response to peginterferon-a-2b plus ribavirin for the initial treatment of chronic hepatitiC. Am. J. GastroenteroL 98(11), 2354–2362 (2003).
- ••Cost-effectiveness analysis of assessingrapid viral response during antiviral therapy for CHC.
- Siebert U, Sroczynski G, Rosso' S et al Cost-effectiveness of peginterferon-a-2b plus ribavirin versus interferon-a-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 52(3), 425–432 (2003).
- •Cost-effectiveness analysis of peginterferon-a2b plus ribavirin for the treatment of naïve patients with CHC in Germany.
- Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon-a-2b plus ribavirin for the treatment of naïve patients with chronic hepatitis C. Aliment PharmacoL Ther. 17(5), 687–694 (2003).
- •Cost-effectiveness analysis of peginterferon-a2b plus ribavirin, including the effect of therapy compliance, for the treatment of naive patients with CHC in Spain.
- Orlewska E, Zaborowski P. The cost and effects of combination of pegylated interferon-a-2a with ribavirin versus combination of conventional interferon (a2b) with ribavirin in the treatment of chronic hepatitis C in adults in Poland (Polish). Farmakoekonomika 7(4), 3–15 (2003).
- •Cost-effectiveness analysis of peginterferon-ala plus ribavirin for the treatment of naive patients with CHC in Poland.
- Sullivan SD, Craxi A, Alberti A et al. Cost- effectiveness of peginterferon-a-2a plus ribavirin versus interferon-a-2b plus ribavirin as initial therapy for treatment-naïve chronic hepatitis C. PharmacoEconomics 22(4), 257–265 (2004).
- •Cost-effectiveness analysis of peginterferon-ala plus ribavirin for the treatment of naïve patients with CHC from the prespective of the Italian National Health Service.
- Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-a-2b in patients with histologically mild chronic hepatitis C. Ann. Intern. Med. 127,855-865 (1997).
- Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefit and costs. JAMA 280,2088–2093 (1998).
- Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon-a-2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J. GastroenteroL 95, 1524–1530 (2000).
- Wong JB, Davis GL, Pauker SG. Cost- effectiveness of ribavirin/interferon-a-2b after interferon relapse in chronic hepatitis C. Am. J. Med. 108,366-373 (2000).
- Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. Ann. Intern. Med. 133, 665–675 (2000).
- Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C. J. HepatoL 33, 651–658 (2000).
- Sagmeister M, Wong JB, Mullhaupt B, Renner EL. A pragmatic and cost-effective strategy of a combination therapy of interferon-a-2b and ribavirin for the treatment of chronic hepatitis C. Eur. GastroenteroL HepatoL 13,483–488 (2001).
- Sennfalt K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon-a-213 therapy for chronic hepatitis C in Sweden. Scand. Castroenterol. 36,870-876 (2001).
- Stein K, Rosenberg W, Wong J. Cost- effectiveness of combination therapy for hepatitis C: a decision analytic model. Cut 50,253–258 (2002).
- Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology36, S145—S151 (2002).
- Davis SL, Wong JB, McHutchison JG et al. Early virologic response to treatment with pegylated interferon-a-213 plus ribavirin in patients with chronic hepatitis C. Hepatology38(3),645–652 (2003).
- Hadziyannis SJ, Cheinquer H, Morgan T et aL Peg interferon-a-2a (40KD) (pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. j Hepatology36, 1(2002).
- Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte"combination interferon-a-213 plus ribavirin regimen possible for the first-line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 31 (1), 211–218 (2000).
- Orlewska E, Mierzejewski P. Project of Polish guidelines for conducting pharmacoeconomic evaluation in comparison to international health economic guidelines. Eur. j Health Econ. 4(4), 296–303 (2003).
- Marcelin P, Boyer N, Gervais A et al. Long- term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann. Intern Med. 127,875–881 (1997).
- Lau DT-Y, Kleiner DE, Ghany MG et aL 10-year follow-up after interferon-a therapy for chronic hepatitis C. Hepatology 28,1121–1127 (1998).
- Chong CA, Gulamhussein A, Heathcote EJ et al. Health-state utilities and quality of life in hepatitis C patients. Am. j Castroenterol. 98,630–638 (2003).
- •Recent assessments of health-state utilities and quality of life in patients with CHC infection.
Websites
- National Institutes of Health Consensus Development Conference Statement. Management of Hepatitis C: 2002. June 1–2 (2002) http://consensus.nih.gov/cons/116/ 116cdc_intro.htm (Accessed September 2004)
- •Review of clinical effectiveness and guidance on the use of pegylated interferon and ribavirin for CHC treatment.
- Ministerio della santa, Departimento per Valutazione dei Medicineli e la Farmacovigilanza www.ministerosalute.it/medicinali/notizie/ file/Informazione_farmaci.pdf (Accessed September 2004)